Funding announcement
Company
GSK
Funding history
Investors
Every investor coverage indicates participated in a round GSK raised.
What GSK bought
Companies GSK acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
Coverage
Stories naming GSK. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Grant
$18.9m
ENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
Funding announcement
Professor got nothing from the $2.8b sale of his molecule, and that's okay
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Fund close
$30m
Andrew Wilks in Weekend Australian
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Fund close
$20m
Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
2 deals
Andrew Forrest backs Sydney biotech startup in $26 million raise
Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.
Also SmartCompany